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SUMMARY
Functional and morphological studies in
children affected by Attention Deficit Hyper-
activity Disorder (ADHD) suggest a prefrontal
cortex (PFc) dysfunction. This cortical region is
regulated by subcortical systems including nor-
adrenergic (NEergic), dopaminergic (DAergic),
cholinergic, serotonergic, and histaminergic path-
ways. A wealth of data in humans and in animal
models demonstrates altered dopamine (DA)
regulation. Drugs that modulate norepinephrine
(NE) transmission are also effective in ADHD
patients, thus leading to the hypothesis of a
NEergic disorder. This review covers the
regulation of PFc functions by NE and the
interaction between the NE and DA systems, as
suggested by pharmacological, electrophysio-
logical, morphological, and gene knock out (KO)
studies. A negative feedback between NE and DA
neurons emerges from KO studies because KO
mice showing increased (NE transporter (NET)
KO) or decreased (DBH and VMAT2 KO) NE
levels are respectively associated with lower and
higher DA levels. Locomotor activity can be
generally predicted by the DA level, whereas
sensitivity to amphetamines is by NE/DA balance.
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Some animal models of ADHD, such as
spontaneously hypertensive rats (SHR), show
alterations in the PFc and in the DA system.
Evidence about a correlation between the NE
system and hyper-locomotion activity in such
animals has not yet been clarified. Therefore, this
review also includes recent evidence on the
behavioral effects of two NET blockers,
reboxetine and atomoxetine, in two animal models
ofADHD: SHR and Naples High Excitability rats.
As these drugs modulate the DA level in the PFc,
certain effects are likely to be due to a rebalanced
DA system. We discuss the significance of the
results for theories of ADHD and make
suggestions for future experimentation.
KEYWORDS
ADHD, norepinephrine system, dopamine system,
norepinephrine transporter inhibitors, prefrontal
cortex, motor activity, attention, behavior, review
INTRODUCTION
The grayish-blue colored small pigmented
region of the fourth ventricle floor, the locus
coeruleus (LC), includes a cluster of about 1600
neurons per nucleus in rats, several thousand in
monkeys, and 10,000 to 15,000 in humans (Foote et
al., 1983; for review see Berridge & Waterhouse,
(C) 2004 Freund & Pettman, U.K. 133134 D. VIGGIANO ET AL.
2003). These neurons contain norepinephrine
(NE), as shown by Dahlstrom and Fuxe in 1964
(1964), and are the origin of widespread nerve
terminals in the mammalian brain and spinal cord
(Loughlin et al., 1982; Fallon & Loughlin, 1982).
Norepinephrine neurons give rise to two major
bundles, the dorsal and ventral one. The former
(dorsal tegmental bundle) originates from LC
neurons and terminates in many regions of the
forebrain, cerebellum, and spinal cord (Cerbone &
Sadile, 1994). The latter or central tegmental tract
originates from diffuse NE cell groups in the pons
and medulla and terminates in the hypothalamus
and spinal cord (Mason, 1981).
Norepinephrine LC cells fire monotonically
(2-4Hz in the tonic mode) in relation to stages of
sleep and waking, with the highest rates occurring
during wakefulness (Robbins, 1997). Moreover,
LC cells respond to novel or noxious stimuli,
conditioned stimuli, and appetitive events (Robbins,
1997; Bouret & Sara, 2002). They play, in fact,
regulatory effects on attention and arousal, fear
and anxiety, information storage and locomotor
activity (for review see Mason, 1981; Cerbone &
Sadile, 1994; Sadile, 1996; Robbins, 1997).
Several drugs interfere with the NE system. The
psychostimulant amphetamine and the dopamine
(DA) transporter blocker, methylphenidate, inhibit
LC firing (Lacroix & Ferron, 1988). Interestingly,
both drugs are largely used in the treatment of a
disorder characterized by hyperactivity and
inattention, known as attention deficit hyperactivity
disorder (ADHD). As a consequence, the possibility
that ADHD represents a NEergic disorder has been
recently discussed (Biederman& Spencer, 1999).
Attention deficit hyperactivity disorder is a
neurodevelopmental problem diagnosed in to 3
percent of children (Castellanos& Tannock, 2002;
Sergeant et al., 2003). The main features are "a
persistent pattern of inattention and/or hyper-
activity/impulsivity that is more frequently
displayed and more severe than in individuals at a
comparable level of development" (American
Psychiatric Association (APA), 1994). The disorder
can occur before the 7 year ofage and in different
environments. Different variants have been
identified: hyperactive-impulsive, inattentive, and
combined (APA, 2004).
The contributions of NE and DA neuro-
transmissions to the motor and cognitive symptoms
of ADHD have been investigated in rodent and
primate models and in humans as well
(Castellanos et al., 1996). Dopamine and NE
interact at their nuclei of origin and at shared
target sites, such as the prefrontal cortex (PFc)
(Berridge & Waterhouse, 2003), wherein the
control of DA and NE is very complex.
Interestingly, the PFc has shown typical functional
alterations in ADHD across many different studies
(see below).
The functions of the PFc and its regulation by
DA and NE are here reviewed in two animal models,
spontaneously hypertensive (SHR) and Naples
High Excitability rats (NHE; see also for review
Viggiano et al., 2002; Viggiano et al., 2003b).
2. THE PFC IN ANIMALMODELS OF ADHD
2.1 Functional anatomy and alterations
The existence of a PFc in rodents has been
widely debated (Brown & Bowman, 2002; Uylings
et al., 2003). In particular, the human PFc can be
divided into different subregions, which share a
common input represented by the mediodorsal
thalamie nucleus (Uylings et al., 2003). In rats,
however, the latter projects only to the medial and
orbital frontal lobe, but not to dorsolateral regions.
The PFc has been involved in attention,
decision making (Mulder et al., 2003), temporal
organization of behavior (Fuster, 2000), working
memory (Goldman-Rakic, 1996), and reversal
learning (McAlonan& Brown, 2003).
Functional subdivision of the PFc in rats,
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main fields: medial (dorsal and ventral), orbito-
frontal, and dorsolatcral. Lesions of the rat medial
PFc impair attention and attentional set shift
(Brown & Bowman, 2002; Uylings t al., 2003),
reduce anxiety, and increase novelty-induced
locomotor activity (Deacon et al., 2003). Lesions of
the dorsomedial (anterior cingulate) PFc impair
discriminative accuracy, whereas the ventromedial
(infralimbic) region sustains inhibitory control
(Chudasama et al., 2003). Orbitofrontal lesions
impair behavioral flexibility, leading to persever-
ative tendencies, thus decreasing performance in
various learning and memory tasks (Chudasama et
al., 2003; Vafaei & Rashidy-Pour, 2004). Lesions
of the dorsolateral PFc lead to shifting strategy
alterations, impairing behavioral flexibility in rats.
Conversely, a corresponding lesion in humans
impairs working memory.
The activity of the PFc is modulated by a set of
subcortical systems comprising acetylcholine-, DA-,
5-hydroxytryptamine (5-HT)-, NE-, and histamine-
containing neurons (Robbins, 1997; Uylings et al.,
2003). Recently, a sixth system has been
characterized, originating from the lateral
hypothalamus, which releases glutamate and orexin
(also called hypocretin) as neuromodulat6rs
(Torrealba et al., 2003). All derive from a relatively
small number of neurons with a terminal
arborization that allows the innervation of the entire
forebrain and spinal cord. These subcortical systems
partially share target regions and influence each
other in a very complex manner. In particular, NE
neurons from the LC project to almost the entire
neocortex, and the NE terminals are denser in layers
IV and V, although the laminar distribution is less
evident in rodents (Foote et al., 1987). Th is
widespread input to the cortex differs from the DA
input, which is restricted at the cortical level to the
medial PFc (Bjorklund & Lindvall, 1984). The only
cortical areas that project back to the LC are the
same medial PFc in rats and the dorso-lateral PFc in
primates (Amsten, 1997). Interestingly, the orexin
system also interacts with both DA (Fadel &
Deutch, 2002) and NE systems (Monda et al.,
2004). Finally, the PFc receives input also and
projects back to the reticular formation (Newman et
al., 1989; Gritti et al., 1997).
Electrophysiologieal evidence shows that PFe
neurons e activated during the delay period of a
delayed-response trial (see Goldman-Rakie, 1996),
thus suggesting its involvement in working
memory functions. Recent data would also suggest
a direct involvement in reward-directed learning.
In fact, neurons in the PFc increase their firing rate
at the presentation, whereas they reduce the firing
rate from the conditioned-stimulus presentation up
to the reward delivery, aider the task has been
learnt (Mulder et al., 2003). Thus, the PFc has
access to reward stimuli. In fact, a loop has been
anatomically and functionally described, involving
the PFc, striatum, globus pallidum, and substantia
nigra (the striatal output), the thalamus (ventro-
medial nucleus), and back to the PFc (Uylings et
al., 2003). This circuit is thought to link
motivationally relevant stimuli to motor areas
(Kalivas et al., 1993). The electrophysiologieal
data reported above rather suggest, however, that
PFe neurons encode for prediction in reward
delivery and transfer this information directly to
the VTA, where the error in prediction is
calculated (Williams et al., 2004).
Interestingly, the process of error prediction is
possibly altered in ADHD, thus suggesting a direct
involvement of PFc modulation in this disorder.
More direct evidence of an involvement of the PFc
in ADHD is the following"
reduced volume of right PFc (Hynd et al., 1990;
Castellanos et al., 1996; Filipek et al., 1997;
Pueyo et al., 2000; Mostofsky et al., 2002),
reduced activation of right prefrontal
metabolism during response inhibition tasks
(Rubia et al., 2000; Langleben et al., 2001), and
reduced [FS]-DOPA uptake ratios in the
medial PFC.
Moreover, the analysis of the PFc in animal
models ofADHD reveals similar alterations in the136 D. VIGGIANO ET AL.
PFc. In fact, rats selected over a mixed population
for their impulsivity in an attentive task show a
lower metabolic activation of the PFc (Barbelivien
et al., 2001). In addition, the PFc of SHR
compared with Wistar Kyoto (WKY) control rats
shows (a) a reduced number of tyrosine
hydroxylase (TH) fibers (King et al., 2000) and (b)
increased NE activity in the PFc (Russell, 2000).
2.2 Modulation ofPFc functions by NE and DA
The PFc receives projections from both the
VTA and the LC and sends back projections to the
VTA and to regions where dendrites of NE LC
cells are present (Jodo et al., 1998). In fact, several
data (see e.g. Jodo et al., 1998) show that the PFc
is a major source ofexcitation ofthe LC.
Strikingly, DA does not modulate NE release
in the PFc (Vanderschuren et al., 1999), whereas
NE can modulate DA release (Bymaster et al.,
2002). In fact, the excitation of LC neurons
increases the release of DA in the PFc, but this
effect does not occur through a direct excitation of
DA neurons or terminals (Kawahara et al., 2001).
A mechanism responsible in part for this effect is
represented by the reuptake of DA by the NE
transporter (NET) (Carboni et al., 1990). As a
consequence, the NE terminals in the PFc would
regulate the resting levels ofDA through the NET.
This offers an interpretation of the increase NE
and DA levels in the PFc after treatment with
drugs that block the NET, such as reboxetine and
atomoxetine (Bymaster et al., 2002). In fact, the
effects of psychostimulants such as D-amphetamine
on DA outflow can be partially controlled by NE
receptors (Darracq et al., 1998). The NE and DA
systems, however, can also interact at the nuclei of
origin and in other target sites.
3. Dopamine and norepinephrine interactions
Direct connections have been found between
the VTA and the LC. In fact, DA neurons in the
VTA express a-2c NE receptors (Lee et al., 1998),
and there is a tonic release of NE in the VTA
(Reith et al., 1997). Indeed, morphological evidence
supports a direct projection from the LC to the
VTA (Phillipson, 1979). In addition, direct
projections from the VTA to the LC exist
(Swanson, 1982) and are able to excite NE
neurons (Deutch et al., 1986).
The nucleus accumbens is the target of DA
neurons from the VTA and NE neurons from the
nucleus tractus solifarius (NST) (Berridge &
Waterhouse, 2003). Thus, local injection of
adrenoceptor agonists modulates DA release
(Yavich et al., 1997), and, conversely, DA
modulates the release ofNE (Vanderschuren et al.,
1999). These interactions at the nuclei of origin
and target sites and the DA reuptake by the NET
make it difficult to disentangle the behavioral
effects of NE and DA drugs. In particular,
inferences about the pathogenesis ofADHD based
on the efficacy of drugs acting on the NE system
should be advanced with caution. To this aim, the
behavioral effects of genetic manipulation of the
NE system and the changes in the NE system
evidenced in animal models of ADHD are
discussed.
BIOCHEMICAL/BEHAVIORAL EFFECTS OF
CHANGES IN THE NE SYSTEM
4.1 Embryogenesis
The use of knock out (KO) technology has
been used to explain many functional aspects of
NEergic neurons (for review see Carson &
Roberson, 2002; see Table for a summary). The
LC neurons are strictly regulated during their
development, although the regulatory cascade is
not yet fully defined. Homeobox gene Phox2a-
deficient mice show an absence of the LC and
defects in sensory/ autonomic ganglia (Morin et
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TABLE 1
Knockout and transgenic mice for norepinephrine system
Gene (--=KO;
++=over-
expression)
Phox2a
Mash-
TH--
TH + DBH
DBH
DBH ++
VMAT2
NET
Orct3
COMT
MAO-B
a lb++
ald--
DA levels NE
levels
Sensitivity to
amphetamines Locomotor activity
No devdopment of
NE system
No development of
NE system
References
(Morin, 1997)
(Hirsch, 1998)
(Kobayashi, 1995;
Zhou, 1995),
(Zhou, 1995)
(Thomas, 1997)
(Kobayashi, 1994)
(Takahashi, 1997)
(Xu, 2000)
(Zwart, 2001)
(Gogos, 1998)
(Cases, 1998)
(Carson, 2002)
(Drouin, 2002)
(Zuscik, 2000)
Impaired response to
noxious stimuli (Tanoue, 2002)
a 2a--
a 2c
a 2c++
KO knockout, DA dopamine, NE norepinephrine
-: no changes; >: increased; <: decreased
(Schramm, 2001;
Lahdesmaki, 2002;
Davies 2003)
(Sallinen, 1999)
(Sallinen, 1999)138 D. VIGGIANO ET AL.
Phox2a controls NEergic traits during develop-
ment, possibly through an interaction with Mash-l,
a gene transiently expressed in the central nervous
system. In fact, the targeted mutation of Mash-1
also causes the absence of central and peripheral
NE neurons (Hirseh et al., 1998). Knockout (KO)
mice have been useful for dissecting the cascade
that controls the NE phenotype.
4.2 Synthesis and clearance
Norepinephrine is synthesized from L-dihydroxy-
phenylalanine (L-DOPA), which is first converted
to DA by the enzyme tyrosine hydroxylase (TH)
and then to NE, through the action of the enzyme
DA-beta-hydroxylase. Therefore, perturbations in
TH (see below, TH KO) will affect the synthesis
of both NE and DA. In fact, TH KO mice lack
both DA and NE (Kobayashi et al., 1995; Zhou,
1995a). The animals survive embryogenesis but
die at 3 to 4 weeks of age from severe hypoactivity
and hypophagia. The synthesis of NE, however,
can be normalized by the transgenic expression of
TH under the control of the DA-b-hydroxylase
promoter, thus generating pure DA KO mice. Such
mice survive, displaying normal NE synthesis, but
make no DA (Zhou, 1995a) and are severely
hypoactive. Unfortunately, no data are available
about their sensitivity to amphetamines.
Interestingly, the induction ofa mutation in the
TH gene, which leads to a 40% reduction in TH
activity, leads to a lowered learning performance
and memory formation. In these animals, spatial
learning and LTP are normal, and the performance
in behavioral tasks can be restored by stimulating
NE activity (Kobayashi et al., 2000). Therefore,
low levels of NE reduce motivation and
performance in learning tasks.
On the other hand, DA beta-hydroxylase
(DBH) KO mice, which selectively lack NE
(Thomas & Palmiter, 1997), do not show
alterations in locomotor activity or learning,
although they swim more slowly and show more
rapid extinction. These animals show characteristic
somatic problems such as ptosis, reduced body
mass, hypotension, increased embryonic mortality,
and deficient thermogenesis (Carson & Roberson,
2002). Interestingly, DA levels are elevated in
most tissues (Thomas et al., 1998). The mice are
hypersensitive to the behavioral effects of amphet-
amine (Weinshenker et al., 2002) and susceptible
to seizure-inducing stimuli (Szot et al., 1999).
Reboxetine and other antidepressants have no
effect in DBH KO mice (Cryan et al., 2001),
which confirms that all the indirect effects ofthese
drugs necessitate the release ofNE. Unfortunately,
no data are available about the effectiveness of
reboxetine or other NET blockers in DA KO mice,
which could disentangle the NE-dependent effects
from the DA-dependent effects.
Conversely, the hyperexpression of DBH in
transgenic mice is not accompanied by changes in
NE levels (Kobayashi et al., 1994). Therefore, it is
possible that the hypolocomotor phenotype of TH
KO mice is, rather, due to the changes in DA
levels or to the lack of compensatory DA changes
in DBH mice.
The vesicular monoamine transporter
(VMAT2) stores monoamines, and particularly
NE, from the neuronal cytoplasm into vesicles.
VMAT2 KO mice die by the second week after
birth and show increased mortality, possibly from
arrhythmias (Takahashi et al., 1997). Heart rate,
body temperature, NET, DA transporter (DAT),
adrenergic, and DAergic receptors are normal, but
DA levels are increased, as is the sensitivity to
amphetamines.
Clearance for NE is accomplished by the NE
reuptake system or NET, by monoamine oxidases
(MAO-A and MAO-B), and by catechol-O-methyl-
transferase (COMT) enzymes. Although the NET
is the predominant transporter in neuronal tissue, a
second process termed uptake-2 is responsible for
the removal of NE, accomplished by the protein
extraneuronal monoamine transporter (EMT) or
the organic cation transporter 3 (OCT-3). Finally,NOREPINEPHRINE IN ANIMAL MODELS OF ADHD 139
COMT methylates NE, thus forming normeta-
nephrine, whereas the intraneuronal degradation of
NE is accomplished by MAO-A and MAO-B.
Mice carrying a functional deletion ofthe NET
(Xu et al., 2000) are viable and fertile. Disruption
of the NET gene prolongs the clearance ofNE and
elevates its extracellular levels. Intracellular levels
of NE are decreased in NET KO mice, however,
suggesting that NE storage levels in neurons is
controlled by reuptake rather than by synthesis.
These animals are hypothermic. Moreover, they
are less active than controls in an open field. This
is accompanied by lower resting levels of DA, and
supersensitive postsynaptic D2/D3 DA receptors,
thus increasing the behavioral effects of
amphetamine.
Knock out mice for the Orct3 gene, which
encodes for the EMT (extraneuronal monoamine
transporter, see above), display normal general
behavior and normal levels ofDA and NE (Zwart
et al., 2001). Mice lacking COMT show increased
levels of DA but not of NE (Gogos et al., 1998).
Monoamine oxidase-A KO mice show increased
levels of NE, 5-HT, DA in the CNS (Cases et al.,
1998), and increased aggression. Conversely,
MAO-B KO mice do not show differences in NE,
5-HT, and DA levels (Grimsby et al., 1997). All
this evidence is in agreement with the hypothesis
that MAO-A is the only oxidase in NE neurons in
the LC.
In summary, lesions that reduce the extra-
cellular NE level (DBH KO, VMAT2 KO mice)
induce the compensatory hyperDAergic system,
normal locomotor activity but hyperresponsivity to
amphetamines. On the contrary, lesions that
increase the intracellular NE level (NET KO mice)
also decrease the DA level, accompanied by low
locomotor activity and hypersensitivity to amphet-
amines. Finally, lesions that decrease both DA and
NE levels (TH KO mice) reduce locomotor activity.
Thus, the NE and DA systems are regulated in
a negative feedback manner. The levels of DA
correlate with locomotor activity, whereas the
responsivity to amphetamines is the outcome of a
balance between the two systems. In fact, selective
and extensive depletion of NE in neonatal rats by
6-OHDA in presence of a DAT inhibitor leads to
increased expression of DA, motor hyperactivity,
and distractability (Raskin et al., 1983; Carli et al.,
1983).
4.3 Receptors
The NE receptors have been classified in three
classes: alpha receptors, which are at postsynaptic
sites, alpha2 receptors, both pre- and postsynaptic,
and three different beta receptors, which are
mainly postsynaptic but can also act pre-
synaptically to facilitate NE release (O’Donnell,
1993; Murugaiah & O’Donnell, 1995). A fourth
beta receptors isoform has been hypothesized
recently (Oostendorp et al., 2000), The fourth
group, beta receptors, represents an important
interface between the sympathetic nervous system
and the cardiovascular system (the so called beta-
adrenergic axis; see Naga Prasad et al., 2001). As
far as beta receptor KO mice are concerned, they
are not included in this review because most of
their alterations pertain to the heart.
Three a subtypes (ata, (l,lb, l,ld) and four a2-
receptor subtypes (tX2.d) are described. These are
also expressed on glial cells, and their expression
is different according to the brain region,a being
expressed mainly in the ventral part of the brain,
ab in the thalamus, amygdala and raphe nuclei and
aid in the cortex and hippocampus (see also
Tanoue et al., 2002). Here, synapses are present on
both pyramidal and nonpyramidal neurons, on
which the a2a receptor is the predominant NE
receptor isoform (Aoki et al., 1998). Mice lacking
the aab, ab, aid, a2a, a2b, a2e adrenergic receptor
subtypes and a mouse line containing a point
mutation in the a2a receptor have been developed.
Moreover, lines overexpressing the aa, ab, tXd
receptors under the control of different promoters
have been studied (Sallinen et al., 1999; Tanoue et140 D. VIGGIANO ET AL.
al., 2002; Drouin et al., 2002). Only one subset of
these lines has been behaviorally tested. None of
the al subtypes is required for embryologic
development, as these KO mice do not show gross
abnormalities.
Mice KO for alb show increased reaction to
novelty and novelty-induced hyperactivity (Spreng
et al., 2001) although other reports failed to confirm
this evidence (Drouin et al., 2002). Moreover, KO
mice do not display changes in the DA system, but
the levels ofNE in the PFc are lower than those in
wild-type mice. The locomotion-stimulating effects
and the increase in DA levels induced by
d-amphetamine-morphine are decreased in these
animals (Drouin et al., 2002; Auclair et al., 2002).
This reduction might depend on a lower efflux of
DA after stimulation (Battaglia et al., 2003).
Conversely, mice overexpressing the tlb
receptor have an age-dependent loss in horizontal
deambulation and a reduced number of rearings,
which can improve after treatment with adrenergic
blockers or with L-DOPA (Zuscik et al., 2000).
Moreover, this phenotype is accompanied by
seizures and neurodegeneration, and NE plasma
levels are reduced.
Mice lacking the tld receptor show an
impaired response to noxious stimuli (Tanoue et
al., 2002). Mice lacking the a2a receptor show
normal locomotor activity (Schramm et al., 2001)
but a reduced number of rearings in open field
(Lahdesmaki et al., 2002).The resting levels ofNE
are normal, but the NE turnover is increased
(Lahdesmaki et al., 2002), and the NE LC neurons
are hypertrophic (Davies et al., 2003). Anxiety
tests in these animals suggest that a2a is stress
protecting (Schramm et al., 2001).
Targeted inactivation ofthe a2c receptor leads to
normal or increased locomotor activity, and super-
sensitivity to amphetamine (Sallinen et al., 1999).
Moreover, these mice exhibit lower DA turnover.
Conversely, transgenic mice overexpressing t2c
receptors show normal or reduced activity and
increased stress susceptibility. Anxiety tests in
these animals suggest that 2e mediates stress
susceptibility (Schramm et al., 2001).
Interestingly, methylphenidate, a drug that
blocks the DA transporter and is widely used in
ADHD pharmacotherapy, decreases the collected
reward in an operant conditioning task in normal
mice, but has opposite effect in 2 receptor KO
mice (Ihalainen et al., 2001). This is in agreement
with the increase in spontaneous locomotor
activity induced by amphetamine in these animals.
It is plausible that the alteration in DA metabolism
can explain the different effect of MPH (see also
the companion paper by Viggiano et al., 2004
this issue).
In summary, both ab and2 receptors control
locomotor activity; KO mice for these receptors
show increased activity, whereas transgenic over-
expressing mice show decreased activity. Their
influence on DA and NE levels is different. The
alb KO mice do not show changes in DA level but
have a lower NE level than the wild-type, whereas
a2 KO mice show a lower DA turnover. The
sensitivity to amphetamines is again reflected by
the balance between DA and NE levels.
NOREPINEPHRINE SYSTEM CHANGES IN
BEHAVIORAL MODELS OF ADHD
Many data are available about the NE system
in an animal model of ADHD, the SHR. These
mice are hyperactive and impulsive in comparison
with their WKY controls. The evidence from LC
neurochemistry does not show an alteration in NE
levels (Kaehler et al., 2000), although the turnover
can be elevated. The firing rate of these neurons is
normal (Conti et al., 1997) or lower (Olpe et al.,
1985). The TH levels are increased in the medulla
(Kumai et al., 1996, 2003) and around vessels
(Gradin et al., 2003) but decreased in the PFc
(King et al., 2000). Recent data also report lower
amounts ofTH in a bounded postnatal period (Leo
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solitary tract (Dev & Philip, 1996) but elevated in
the median preoptic area (Tanaka et al., 2002),
striatum and brainstem (Howes et al., 1984). The
release of NE per varicosity might be increased
(Jimenez-Altayo et al., 2003). The {X receptors in
the cortex of SHR are increased (Hellstrand &
Engel, 1980), a datum that contrasts with the
hypoactivity of lb over-expression in mice. Some
of these alterations might explain the elevated
blood pressure in these .animals, but do not
correlate with the hyperactivity (Reja et al., 2002).
The data presemed in Table 2 raise the
question about why ADHD subjects respond to
pharmacological agents that modify the NE
system. In order to address this point, we will
show data about the biochemical and behavioral
effects of NET blockers and revise these effects
from the view-point of an alteration in the
attentional networks.
6. NET BLOCKADE IN HYPERACTIVE RATS
6.1 Norepinephrine and dopamine systems
Reboxetine and atomoxetine are potent and
selective inhibitors of the NET (Wong et al.,
2000). In contrast, the affinity of the psycho-
stimulant methylphenidate is higher for the DAT
than for the NET (Bymaster et al., 2002).
Reboxetine and atomoxetine exert a similar action
on the levels ofNE and DA in the PFc, but differ
as regards the effects on 5-HT levels. In fact, both
reboxetine and atomoxetine enhance DA output in
the PFc, but not in the accumbens (Kuczenski &
Segal, 1995; Wong et al., 2000). Possibly this
effect is dependent on a blockade ofDA reuptake
by the NET in the PFc, a mechanism absent in the
striatum, where NE terminals are few (Carboni et
al., 2003). It is possible, however, that indirect
mechanisms intervene, as 2-adrenergic antagonists
also increase DA release in terminal fields (Shi et
al., 2000; Linner et al., 2001).
The increased DA level is accompanied by an
increased burst firing but not an average firing
frequency of DA cells in the VTA (Linner et al.,
2001). Similar changes might be responsible for
altered reward perception, with a mechanism
similar to methylphenidate (see also companion
paper (Viggiano et al., 2004 this issue).
Similarly, the blockade ofNET by these drugs
increases the levels of NE (Kuczenski & Segal,
1995). High doses lead to a reduction of the firing
rate of LC NE cells and 5-HT cells in a dose-
dependent relation (Wong et al., 2000), an effect
similar to that of other stimulants (Aston-Jones &
Bloom, 1981). Interestingly, a2-adrenergic antago-
nists and methylphenidate (Kuczenski & Segal,
2001) also enhance NE release (Thomas, 1991).
Reboxetine does not lead to increased extracellular
levels of5-HT (Kuczenski & Segal, 1995).
Similar studies with atomoxetine show that
specific PFc modulators have a different sensibility
to these drugs. In fact, NE is already increased at
low doses (0.3 mg/kg), whereas DA is increased at
medium doses (1 mg/kg) and 5-HT at high doses
(3mg/kg) (Bymaster et al., 2002). The maximal
release occurs hour after injection. Interestingly,
the effects on DA are evident only in the PFc, as
no changes can be detected in the striatum.
6.2 Behavior
Nowadays, low-doses of AMPH-Iike stimulants
and methylphenidate are the main pharmacological
treatment of ADHD. These drugs ameliorate the
symptoms of inattentiveness, hyperactivity, and
impulsivity. Unfortunately, about 10 to 30 percent
of ADHD children are either non-responders or
intolerant to psychostimulant therapy (Barkley,
1977), which may reflect the heterogeneous neural
substrates ofADHD.
Other therapies primarily affect the NE system,
thus indirectly modulating the DA system. In fact,
NE a2-agonists like guanfacine (Hunt et al., 1995)
are also effective in the treatment ofthe disorder.142 D. VIGGIANO ET AL.
TABLE 2
Changes ofthe norepinephrine system in SHR rats
LC
(Kaehler, 2000) NE content in LC
(Kaehler, 2000) Release ofNE in LC
NE turnover in LC > (Kaehler, 2000)
Firing rate ofLC neurons .Cona, 1997)
<(Olpe, 1985)
NE in striatum, brainstem >nowes, 1984)
Release of 5-HT > (Reja, 2002)
> (Kumai, 1996) TH in medulla oblongata
TARGETS
(Dev, 1996) NE content ofNucleu,S o,f,th,,e,,,so!itary, tract
TH+ fibers in frontal cortex
NE release in Median pre0ptic area
Inhibition ofNE Release by z-2 receptors
NE release per varicosity
TH fibers around vessels
(King, 2000)
Alfa-1 receptors in cortex
>(Tanaka, 2002)
< (Russell, 2000)
> (Jimenez-Altayo, 2003)
>(Cn’adin, 2003)
TH activity in adrenal medulla > (Reja, 2002; Kumai, 2003)
> (Hellstrand, 1980)
Correlation ofTH 8ene ,,expression ofblood pressure
-: no changes; >: increased; <: decreased
Positive (Re.ja, 2002)
TABLE 3
Behavioral effects ofReboxetine
SHR
Number ofrearings
Horizontal activity < (-25%)
Duration of > (+26%)
rearings
Behavioral effects ofAtomoxetine
WKY
< (-47%)
< (-4o0 )
> (+17%)
Number ofrearings not tested
Horizontal activity not tested
Duration of not tested
rearings
Legend
not tested
not tested
not tested
-: no changes; >: ,increased; <: decreased
NHE NRB
<(-19%)
> (+22%)
< (-27%)
<(-17%)NOREPINEPHRINE 1N ANIMAL MODELS OF ADHD 143
Finally, antidepressants like reboxetine and
atomoxetine have also been used. In particular,
atomoxetine (tomoxetine, LY139603) is effective
in treating ADHD in adults (Spencer et al., 1998).
To study the differential effects of NET
blockers in normal and hyperactive rats, we used
two animal models of hyperactivity and attention
deficit, previously characterized by a hyper-
functioning mesocorticolimbic (SHR) or meso-
cortical (NHE) DA system (Viggiano et al., 2000,
2003a,b). To this aim, male SHR and NHE rats,
with WKY and Naples Random Bred (NRB) rats
as their respective controls, received daily i.p.
injections of the NE reuptake inhibitor reboxetine
(Pharmacia Upjohn, Milano, Italy, 10mg/kg) or
atomoxetine (Lilly, mg/kg) for 14 days. Rats
were tested in a spatial novelty (Lt-maze) 90 min
after the last injection of drug or vehicle. The
behavioral test lasted for 30 minutes, during which
it was videotaped and analyzed off-line for indices
of activity (traveled distance, rearing frequency)
and non-selective attention (scanning durations).
In SHR and control rats (WKY), reboxetine
induced a significant reduction in traveled distance
compared with vehicle-treated controls (-25% and
-40% respectively). This reduction mainly
pertained to the first 15 minutes of exploration. In
contrast, reboxetine did not reduce the traveled
distance in NHE rats nor in NRB controls.
Reboxetine reduced the orienting frequency
only in WKY rats (-47% compared with vehicle),
without effects on SHR rats. In contrast, the drug
reduced the frequency of rearings in NHE (-19%)
but not in NRB rats. Reboxetine increased the
duration of rearing episodes in both SHR and
WKY rats (+25% and +17% respectively). In
contrast, the drug increased the duration of
rearings in NRB (+22%) but not in NHE rats.
Therefore, the net effects were different if we
consider the number of rearings, the horizontal
exploratory activity, or the duration of rearing
episodes. The number of rearing was decreased,
but only in NHE and WKY rats, whereas SHR and
NRB rats did not show any change. In SHR and
WKY rats, reboxetine reduced horizontal activity
and prolonged scanning time. In contrast, in NHE
and NRB rats reboxetine increased rearing
durations in the control line, whereas it decreased
the rearing frequency in NHE rats. Similarly,
atomoxetine did not modify the horizontal and
vertical activity of NRB rats, whereas it reduced
the number of rearings (-27%) and the traveled
distance (-17%), without effects on scanning
durations inNHE rats (see Table 3).
The data suggest different activity of the NE
system in the SHR versus NHE lines. In fact, SHR
and NHE rats have different responses, reflecting
different neural substrates. The differential
sensitivity of these two lines to reboxetine could
be due to a different involvement of the DA and
NE systems in these animals. Although the effects
of the NET blockade are similar in both the
hyperactive SHR and the control rats, the main
effects are evident in NHE rats, but not in their
NRB controls.
The overall results would suggest that the NE
system is similar in SHR and WKY rats, whereas
differences exist between NHE and NRB rats.
Alternatively, the interaction between the NE and
DA systems is altered in NHE rats. These
conclusions are in agreement with previous
suggestions that an alteration of the NE system in
adult SHR rats is indeed linked to the hypertensive
phenotype but not to hyperactivity.
As both the NE and the DA systems are
involved in arousal, attention, and cognitive
functions, the drugs may act on two different
pathways, thus changing the level of motivation
(Wong et al., 2000). In fact, the LC-NE system is
sensitive to novel environmental stimuli. An
enhanced NE neurotransmission in a novel
environment (see Lt maze) decreases attention to
an individual object, increasing the scanning of the
environment (Berridge & Waterhouse, 2003).
Therefore, the lower frequency of rearings and
the increase of their duration in NHE rats may144 D. VIGGIANO ET AL.
indicate a lower firing rate ofLC neurons, whereas
the changes in SHR and WKY rats can be
explained by the involvement of other systems,
such as DA. The data lead to the suggestion that
the positive effects of NEergic drugs may be due
to an indirect action on the DA system. Nonetheless,
further research is warranted by these findings to
disentangle this intricate issue.
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